Colorectal cancers that develop in Lynch syndrome show a better disease‐specific survival than sporadic colorectal cancer, most likely due to the immunogenic signatures in MMR‐defective tumors (Boland, 2016; Maccaroni et al., 2015). This evidence concerns the gene MRC1 and colorectal cancer.